Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18815192 | 0.67 | — | — | |
| SCHEMBL6639252 | 0.67 | ADRA2A (0.32) | — | |
| SCHEMBL7624475 | 0.67 | L3MBTL1 (0.39) | — | |
| SCHEMBL20878701 | 0.65 | MEN1 (0.38) | — | |
| Hydrochloric Acid SCHEMBL4787170 | 0.65 | L3MBTL1 (0.38) | — | |
| SCHEMBL11742539 | 0.64 | ADRA2A (0.40) | — | |
| SCHEMBL19612832 | 0.64 | — | — | |
| SCHEMBL2778023 | 0.64 | ADRA2A (0.38) | — | |
| SCHEMBL11743173 | 0.64 | ADRA2A (0.38) | — | |
| SCHEMBL21443560 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673277-A1 | [1, 2, 4]TRIAZOLO [4, 3 -B]PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | Novartis AG (CH) | 2013-12-18 | — | — | EP | claimed |
| WO-2012107500-A1 | [1, 2, 4] TRIAZOLO [4, 3 -B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | NOVARTIS AG (CH) | 2012-08-16 | — | — | WO | claimed |
| CN-101772856-A | Be used to electrode and the battery making the new composition of electrode and comprise said composition | CENTRE NAT RECH SCIENT | 2010-07-07 | — | — | CN | claimed |
| CN-1649830-A | Substituted aryl ketones | BAYER CROPSCIENCE AG (DE) | 2005-08-03 | — | — | CN | claimed |
| US-6506762-B1 | Mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. Novel compounds are for eating | NEUROGEN CORPORATION | 2003-01-14 | — | — | US | claimed |
| US-5807966-A | HEATING POLYESTER, POLYAMIDE AND/OR POLYCARBONATE WITH DIPHOSPHONITE AND ANOTHER DIFUNCTIONAL ADDITIVE; CROSSLINKINGINHIBITION | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-09-15 | — | — | US | claimed |
| US-5760164-A | STORAGE STABILITY | EMS-INVENTA AG (CH) | 1998-06-02 | — | — | US | claimed |
| CN-1091288-A | The oxytocin antagonist | OTSUKA PHARMA CO LTD (JP) | 1994-08-31 | — | — | CN | claimed |
| WO-2024146880-A1 | FLUORO-OXYSTEROLS POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-07-11 | — | — | WO | disclosed |
| CN-115724847-A | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2023-03-03 | — | — | CN | disclosed |
| CN-101631464-B | 2,3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives for the treatment of hyperproliferative diseases and angiogenesis-related diseases | 拜耳知识产权有限责任公司 | 2022-12-06 | — | — | CN | disclosed |
| EP-2755976-B1 | 6-SUBSTITUTED 3-(QUINOLIN-6-YLTHIO)-[1,2,4]TRIAZOLO[4,3-A]PYRIDINES AS C-MET TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-20150250799-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| WO-2015024016-A2 | 2-PIPERIDINYL SUBSTITUTED N,3-DIHYDROXYBUTANAMIDES | DUKE UNIVERSITY (US) | 2015-02-19 | — | — | WO | disclosed |
| EP-0515681-A1 | PEPTIDE COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-02 | — | — | EP | disclosed |
| CN-1057259-A | Piperidines oxygen base and quinine epoxy group(ing) different oxazole derivatives, their preparation and the application aspect treatment thereof | SANKYO CO (JP) | 1991-12-25 | — | — | CN | disclosed |
| EP-0176253-B1 | PRODUCTION OF ETHYLENE OXIDE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-14 | — | — | EP | disclosed |
| EP-0330522-A2 | Improved demulsified lubricating oil compositions | EXXON CHEMICAL PATENTS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| US-4822900-A | Production of ethylene oxide | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-04-18 | — | — | US | disclosed |
| EP-0176253-A1 | Production of ethylene oxide | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250799-A1 | Triazolopyridine Compounds | FLT3, RET, MET | ALDH1A1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.